Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. It’s a busy day for biotech news, let’s get right to it.
The need-to-know this morning
- Merck, AstraZeneca, and Incyte reported earnings for the second quarter.
- Novo Nordisk lowered its sales and operating profit forecast for the rest of 2025. The Danish pharma giant also named a new CEO.
-
Results from a Fulcrum Therapeutics study suggest a pill can treat sickle cell disease, but experts caution the drug’s effect was modest and more data will be need to prove patient benefit.
- Apellis Pharmaceuticals won approval from the FDA to expand the use of its drug Empaveli to include treatment for patients with the rare kidney conditions C3 glomerulopathy and primary IC-MPGN.
FDA now says Sarepta can ship therapy to young patients
In a reversal, the Food and Drug Administration yesterday cleared the way for Sarepta Therapeutics to resume shipments of its gene therapy for Duchenne muscular dystrophy to younger patients who can walk.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
